Health insurance; coverage of medications prescribed for treatment of cancer & diseases of blood.
What changed between versions
New section 38.2-3407.23 requires insurers, corporations, and health maintenance organizations to allow provider-administered cancer and blood disease drugs to be dispensed by in-network treating providers, either routinely or when there is a documented three-day delay from specialty pharmacy delivery.
New section 38.2-3407.23 requires self-administered cancer and blood disease drugs to be sent to the pharmacy of the patient's choosing, consistent with existing pharmacy freedom-of-choice provisions.
New section 38.2-3407.23 explicitly defines 'prescribed for the treatment of cancer or diseases of the blood' to include supportive therapies like anti-emetics, antibiotics, and pain medications.
Payment rates for new cancer drug coverage provisions reference 'national average drug acquisition cost' instead of 'wholesale acquisition cost' used in the original pharmacy freedom-of-choice sections.
The document underwent significant reformatting with different spacing, line breaks, and character positioning between the two versions, though the substantive legislative text remained consistent.
